Moody Aldrich Partners’s IGM Biosciences IGMS Stock Holding History

Moody Aldrich Partners’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-22,952	Closed	-$1.51M	–	166
2021 Q3	$1.51M	Sell	22,952 -12,060	-34%	-$923K	0.19%	110
2021 Q2	$2.91M	Sell	35,012 -422	-1%	-$31.3K	0.41%	87
2021 Q1	$2.72M	Buy	35,434 +13,534	+62%	+$1.23M	0.39%	84
2020 Q4	$1.93M	Sell	21,900 -15,837	-42%	-$1.11M	0.31%	94
2020 Q3	$2.79M	Buy	37,737 +18,864	+100%	+$1.12M	0.58%	79
2020 Q2	$1.38M	Buy	+18,873	New	+$1.15M	0.29%	91

Other funds holding IGMS

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Moody Aldrich Partners's IGMS Position: Q4 2021 in Review

Moody Aldrich Partners sold out of IGM Biosciences (IGMS) in Q4 2021, closing a stake of 22,952 shares — an estimated $1.51M sold.

Moody Aldrich Partners first reported a position in IGMS in Q2 2020 and held it in 6 quarters. The position peaked at $2.91M in Q2 2021. 87 funds tracked by Wall St. Rank hold IGMS as of Q4 2021.

Moody Aldrich Partners reported no remaining IGM Biosciences position as of Q4 2021 after selling out during the quarter.
Moody Aldrich Partners sold 22,952 IGM Biosciences shares in Q4 2021, an estimated $1.51M.
Moody Aldrich Partners first reported a position in IGM Biosciences in Q2 2020 and held it in 6 quarters.
Moody Aldrich Partners's IGM Biosciences position peaked at $2.91M in Q2 2021.
87 funds tracked by Wall St. Rank held IGM Biosciences as of Q4 2021.

Based on Moody Aldrich Partners's 13F filing for Q4 2021, filed 2 Feb 2022.